

Novartis India Limited

Inspire – BKC, 7th Floor, Bandra Kurla Complex Bandra East Mumbai 400 051

Tel: 0091 22 50243000 Website: www.novartis.in CIN – L24200MH1947PLC006104 Email: india.investors@novartis.com

March 27, 2025

To.

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip code: 500672

Dear Sir/ Madam,

Sub.: Intimation of meeting of the Board of Directors of Novartis India Limited ('the Company') and Closure of Trading Window.

This is to inform that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company is scheduled to be held on Friday May 09, 2025, *inter alia*, to:

- a) consider and approve the Audited Financial Results of the Company for year ended March 31, 2025; and
- b) recommend dividend on equity shares of the Company, if any, for the financial year ended March 31, 2025.

In this connection, please note that pursuant to the 'Code of Conduct to regulate, monitor and report share trading by Designated Persons and their immediate relatives' ('Code') read with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading Window for dealing in shares of the Company by Designated Persons and their immediate relatives will be closed from **Tuesday**, **April 01**, **2025** till the **end of 48 hours after the declaration of the financial results** of the Company for the quarter and year ending as of March 31, 2025.

You are requested to take note of the above information.

Thanking You.

Yours Sincerely,

For Novartis India Limited



Chandni Maru Company Secretary and Compliance Officer Membership No: A60291